Author

Zeljko Krznaric

NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTIN DERIVED FROM HUMAN NEUTROPHIL ELASTASE (CPA9-HNE) IS A NOVEL SERUM CALPROTECTIN BIOMARKER OF INFLAMMATION AND DISEASE ACTIVITY FOR IBD
NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTIN DERIVED FROM HUMAN NEUTROPHIL ELASTASE (CPA9-HNE) IS A NOVEL SERUM CALPROTECTIN BIOMARKER OF INFLAMMATION AND DISEASE ACTIVITY FOR IBD

Zeljko Krznaric  et al.

SEROLOGICAL MARKERS OF EXTRACELLULAR MATRIX REMODELING REFLECTS ENDOSCOPIC DISEASE ACTIVITY AND SEVERITY IN CROHN'S DISEASE AND ULCERATIVE COLITIS
SEROLOGICAL MARKERS OF EXTRACELLULAR MATRIX REMODELING REFLECTS ENDOSCOPIC DISEASE ACTIVITY AND SEVERITY IN CROHN'S DISEASE AND ULCERATIVE COLITIS

Zeljko Krznaric  et al.

PIVKA-II AS A MARKER OF CHRONIC LIVER DISEASE SEVERITY
PIVKA-II AS A MARKER OF CHRONIC LIVER DISEASE SEVERITY

Zeljko Krznaric  et al.

ASSESSEMENT OF CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX AND MARIA SCORE IN SURGICALLY NAIVE PATIENTS WITH CROHN'S DISEASE
ASSESSEMENT OF CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX AND MARIA SCORE IN SURGICALLY NAIVE PATIENTS WITH CROHN'S DISEASE

Zeljko Krznaric  et al.

FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN’S DISEASE – A TERTIATY CENTER EXPERIENCE
FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN’S DISEASE – A TERTIATY CENTER EXPERIENCE

Zeljko Krznaric  et al.

PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSAL HEALING RATES IN CROHN'S DISEASE
PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSAL HEALING RATES IN CROHN'S DISEASE

Zeljko Krznaric  et al.

ANORECTAL DISORDERS AMONG IBD PATIENTS IN REMISSION, WITH FECAL INCONTINENCE AND TREATED WITH BIOLOGICS – PILOT STUDY FROM A TERTIARY REFERRAL CENTER
ANORECTAL DISORDERS AMONG IBD PATIENTS IN REMISSION, WITH FECAL INCONTINENCE AND TREATED WITH BIOLOGICS – PILOT STUDY FROM A TERTIARY REFERRAL CENTER

Zeljko Krznaric  et al.

AUTOIMMUNE LIVER DISEASES RISE RISK FOR ACCELERATED ATHEROSCLEROSIS: A PILOT STUDY
AUTOIMMUNE LIVER DISEASES RISE RISK FOR ACCELERATED ATHEROSCLEROSIS: A PILOT STUDY

Zeljko Krznaric  et al.

EFFECT OF STANDARD AND MODIFIED BUDESONIDE THERAPEUTIC PROTOCOL ON MAINTENANCE OF ONE-YEAR REMISSION IN PATIENTS WITH MICROSCOPIC COLITIS-PILOT STUDY FROM A TERTIARY REFERRAL CENTER
EFFECT OF STANDARD AND MODIFIED BUDESONIDE THERAPEUTIC PROTOCOL ON MAINTENANCE OF ONE-YEAR REMISSION IN PATIENTS WITH MICROSCOPIC COLITIS-PILOT STUDY FROM A TERTIARY REFERRAL CENTER

Zeljko Krznaric  et al.

ESPEN guidelines on nutrition in cancer patients
ESPEN guidelines on nutrition in cancer patients

Zeljko Krznaric  et al.

LOW INTERQUARTILE RANGE OF LIVER STIFFNESS MEASUREMENT IS INDEPENDENTLY ASSOCIATED WITH 30-DAY MORTALITY AMONG HOSPITALIZED NON-CRITICALLY ILL PATIENTS WITH COVID-19
LOW INTERQUARTILE RANGE OF LIVER STIFFNESS MEASUREMENT IS INDEPENDENTLY ASSOCIATED WITH 30-DAY MORTALITY AMONG HOSPITALIZED NON-CRITICALLY ILL PATIENTS WITH COVID-19

Zeljko Krznaric  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Zeljko Krznaric  et al.

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Zeljko Krznaric  et al.

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY
THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Zeljko Krznaric  et al.

Item 21 - 34 / 34
1
2